期刊文献+

不同来源的细胞因子诱导的杀伤细胞对肝癌细胞SMMC7721的杀伤效应比较 被引量:6

Comparison of killing effects of cytokine-induced killer cell from three different sources on hepatoma cell SMMC7721
暂未订购
导出
摘要 目的探讨脐带血、健康人和肝癌患者外周血来源的细胞因子诱导的杀伤细胞(CIK)在体外的增殖能力,及其对肝癌SMMC7721细胞的杀伤效应。方法无菌采集脐带血、健康人和肝癌患者的外周血,用淋巴细胞分离液分离单个核细胞,加入相应的细胞因子体外诱导CIK,细胞计数法检测CIK的增殖能力,流式细胞术检测细胞的表型,四甲基偶氮唑蓝法检测诱导的CIK对SMMC7721细胞的杀伤效应。结果诱导14 d后,脐带血、健康人和肝癌患者外周血来源的CIK细胞增殖倍数分别为153.8±13.1、137.6±10.3和95.3±8.5,经两两比较差异均有统计学意义(P<0.05)。诱导培养14 d后,脐带血、健康人和肝癌患者外周血来源单个核细胞的CD3^+CD56^+表型细胞所占百分比分别为(45.3±4.6)%、(36.2±2.8)%、(21.9±2.7)%,CD3^+CD56^+表型细胞所占百分比较诱导前有显著提高,差异均有统计学意义(P<0.05);脐带血来源的CIK中CD3^+CD56^+表型细胞所占比例显著高于健康人和肝癌患者,差异均有统计学意义(P<0.05)。经14 d的诱导培养后,3种来源的CIK对肝癌细胞SMMC7721的杀伤活性经两两比较差异均有统计学意义(P<0.05),脐带血的杀伤活性最强,健康人的杀伤活性次之,肝癌患者的杀伤活性最弱。在效靶比10:1时杀伤活性强于效靶比5:1(P<0.05)。结论脐带血来源的CIK体外增殖快,对肝癌细胞SMMC7721的杀伤活性强,是肿瘤细胞生物治疗的最佳选择。 Objective To explore the reproductive activity in vitro and killing effects to hepatoma cell SMMC7721 of cytokine-induced killer cell(CIK) from cord blood,peripheral blood of health people and liver cancer patients.Methods The cord blood and peripheral blood of health people and patients with hepatoma were collected under asepsis condition and the mononuclear cells were separated by lydroxypropylmethyl cellulose.CIK were induced by adding a variety of cytokine in different time.The reproductive activity of CIK were measured by cell counting.Flow cytometry was used to detect the cell phenotype of CIK.The methyl thiazolyl tetrazolium was used to detect the killing effect of CIK to SMMC7721 cells.Results After 14 days of induction,the proliferation multiple of CIK from cord blood,peripheral blood of health people and liver cancer patients was 153.813.1,137.6±10.3 and 95.3±8.5 respectively,the difference of them was statistic significance(P0.05).After 14 days of induction and cultivation,the percentage of mononuclear cells with CD3~+ CD56~+ phenotype from cord blood,peripheral blood of health people and liver cancer patients was(45.3 ±4.6)%,(36.2±2.8)%,(21.9±2.7)%respectively, and it was significantly higher than before induction(P0.05);the percentage of mononuclear cells with CD3~+ CD56~+ phenotype from cord blood was significantly higher than that from peripheral blood of health people and liver cancer patients(P0.05).After 14 days induction and cultivation,the differences of the killing effect of CIK from three source to hepatoma cell SMMC7721 cells were statistic significance(P0.05).The killing activity of cord blood was strongest,health people followed, liver cancer patients was weakest.The killing activity at effect-target ratios 10:1 was stronger than at 5:1(P 0.05).Conclusion CIK derived from cord blood possess high speed of proliferation in vitro and strong killing effect to hepatoma cell SMMC7721,thus being the best choice for tumor biologic therapy.
出处 《新乡医学院学报》 CAS 2013年第10期801-803,共3页 Journal of Xinxiang Medical University
基金 新乡市科技局科技攻关项目(编号:09S052)
关键词 细胞因子诱导的杀伤细胞 肝癌细胞 细胞生物治疗 cytokine-induced killer cell hepatoma carcinoma cell biologic therapy
  • 相关文献

参考文献6

二级参考文献39

  • 1Jing-Ting Jiang,Yue-Ping Shen,Chang-Ping Wu,Yi-Bei Zhu,Wen-Xiang Wei,Lu-Jun Chen,Xiao Zheng,Jing Sun,Bin-Feng Lu,Xue-Guang Zhang.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J].World Journal of Gastroenterology,2010,16(48):6155-6162. 被引量:83
  • 2邹征云,刘宝瑞,钱晓萍,杜娟,王燕.从50 mL外周血中高效扩增CIK方法的探讨[J].肿瘤防治杂志,2005,12(7):515-518. 被引量:8
  • 3岳欣,李慧,于津浦,任秀宝,郝希山.不同输注途径对CIK细胞治疗后的体内分布的影响[J].中国免疫学杂志,2007,23(3):224-228. 被引量:25
  • 4NAGARAJ S,ZISKE C,SCHMIDT-WOLF IG.Human cytokine-induced killer cells have enhanced in vitro cytolytic activiity via non-viral interleukin-2 gene transfer[J].Genet Vaccines Ther,2004,2(1):12.
  • 5CAO XT.Dendritic cells and immunotherapy of liver cancer[J].Chin J Hepatol,2003,11 (3):133-134.
  • 6SHEU BC,HSU SM,HO HN,et al.Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma[J].Cancer,1999,86 (8):1537-1543.
  • 7ROBINSON E,SEGAL R,STRUMINGER L,et al.Lymphocyte subpopulllationsin patients with multiple primary tumors[J].Cancer,1999,85 (9):2073-2076.
  • 8Nonaka K,Saio M, Suwa T, et al. Skexing the Th cell phenotype towardThl alters the maturation of tumor-infiltrating mononuclear phagocytes[J]. J Leukoc Biol,2008;84(3) :679-88.
  • 9Becker Y. Molecular immunological approaches to hiotherapy of humancancers-a review,hypothesis and implications[ J). Anticancer Res,2006;26(2A) :11134.
  • 10Sharma A,Rajappa M,Satyam A,et al. Cytokines( TH1 and TH2) in pa-tients with advanced cervical cancer undergoing neoad-juvant chemoradi-ation: correlation with treatment response [ J ] . Int J Gynecol Cancer,2009;19(7) :1269-75.

共引文献51

同被引文献42

  • 1Reni M,Balzano G,Aprile G. Adjuvant PEFG (Cisplatin, Epi- rubicin, 5-Fluorouracil, Gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer:A randomized phase II trial[ J]. Ann Surg Oneol, 2012, 19:2256-2263.
  • 2Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carci- noma[J]. Cadd Interv Radiol, 2012, 35:555-562.
  • 3Saimura M, Anan K, Mitsuyama S. A multicenter study of epi- rubicin-docetaxe (ET) as promary chemothrapy for patients with inflammatory breast cancer(IBC) [J]. Cancer Chemoth, 2012, 39 : 1075-1079.
  • 4Reni M, Balzano G, Aprile G, et al. Adjuvant PEFG( eisplatin, epirubi- cin ,5-fluorouracil, gemcitabine) or gemcitabine followed by chemora- diation in pancreatic cancer: a randomized phase Ⅱ trial [ J ]. Ann Surg Oncol, 2012,19 ( 7 ) : 2256 -2263.
  • 5Seki A, Hori S. Switching the loaded agent from epirubicin to cispla- tin:salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma [ J ]. Cadd In- terv Radio1,2012,35 ( 3 ) :555-562.
  • 6Saimura M, Anan K, Mitsuyama S, et al. A multicenter study of epiru- bicin-docetaxel(ET) as primary chemotherapy for patients with in- flammatory breast cancer(IBC) [J]. Gan To Kagaku Ryoho,2012,39 (7) : 1075-1079.
  • 7杨涛,邵江河,李启英,余慧青,王思雄,张蒙,武宁,项颖.树突状细胞联合CIK细胞应用于晚期恶性实体瘤治疗的临床疗效观察[J].肿瘤,2010,30(8):700-705. 被引量:37
  • 8原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946. 被引量:988
  • 9刘亚贤,赵宏然,赵海.奥沙利铂联合表柔比星在原发肝癌介入治疗的疗效观察[J].齐齐哈尔医学院学报,2012,33(1):35-36. 被引量:7
  • 10程洪涛,郭晨阳,黎海亮,肖金成,胡鸿涛,郑琳,宗登伟,余朴.TACE联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,21(3):216-219. 被引量:41

引证文献6

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部